Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28.
about
Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsAdvances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesImmunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.Selective atonal gene delivery improves balance function in a mouse model of vestibular disease.Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell ImmunogensType I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicityComparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.A Recombinant Adenovirus Encoding Multiple HIV-1 Epitopes Induces Stronger CD4(+) T cell Responses than a DNA Vaccine in Mice.Native and engineered tropism of vectors derived from a rare species D adenovirus serotype 43.Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expressionGenetic vaccine for respiratory syncytial virus provides protection without disease potentiation.Molecular evolution of human species D adenoviruses.Therapeutic live vaccines as a potential anticancer strategy.Pre-existing immunity against vaccine vectors--friend or foe?Prospects for oral replicating adenovirus-vectored vaccines.Progress on adenovirus-vectored universal influenza vaccines.Getting genetic access to natural adenovirus genomes to explore vector diversity.Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane.Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCsThe Journey of Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
P2860
Q26782083-76ED8DA1-36B3-4DE1-8285-CB194704C4C0Q27013568-973F8F9E-5AF0-4515-AE74-F7D3B65C38ECQ34505337-48731456-F53B-42D1-B62F-FBD7EE2CA106Q35106245-AB6E494B-BE3E-4694-B6B8-DB00064063A6Q35183935-6CC64FB5-CC3E-40C5-9096-10182EF1E1BAQ35914367-439F75C5-8B4F-4D38-ADA3-653A637B0296Q36016455-EF2247C9-0CB4-426D-BEFD-60DCDBBA3D9BQ36674446-35F577E9-52C9-48BE-87F2-6DB2CED5DA13Q36956883-A75C7C5F-E32B-4E78-9502-0CD61DDD9B94Q37619767-BBEE2EBA-6A95-42A9-9E10-5E12957D8F4AQ37624973-5D57BA1E-1425-441F-8032-B71526072EAFQ37690464-ED691BC5-B327-44EC-8B96-D5A2EB498C07Q37875388-B784DCE1-4D1D-4E69-A43F-CD1A2FE69C0CQ38011653-46089142-5B16-4109-9100-F13B80082B09Q38061876-6478174E-76CE-47B5-B0B5-ECACAE695295Q38109356-0F832943-98FA-4057-991C-51666BA5C3A3Q38421971-204FDDA9-3D57-434D-82D2-6F6749D48D44Q39437315-CCC7A7B5-13A3-47D6-BFD9-337016B868FFQ47242905-E0BDB9E0-5689-4068-88AC-92A8F7B7294EQ47607706-0155FB3A-85B9-4278-9DD5-628C16833596Q57175561-7FE5826E-0140-4084-AA09-0ADC4B8C656BQ58750585-E0867F5A-0696-44EB-9E59-5A769655DA89
P2860
Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Potent immune responses and in ...... sed on rare human serotype 28.
@ast
Potent immune responses and in ...... sed on rare human serotype 28.
@en
Potent immune responses and in ...... sed on rare human serotype 28.
@nl
type
label
Potent immune responses and in ...... sed on rare human serotype 28.
@ast
Potent immune responses and in ...... sed on rare human serotype 28.
@en
Potent immune responses and in ...... sed on rare human serotype 28.
@nl
prefLabel
Potent immune responses and in ...... sed on rare human serotype 28.
@ast
Potent immune responses and in ...... sed on rare human serotype 28.
@en
Potent immune responses and in ...... sed on rare human serotype 28.
@nl
P2093
P2860
P1433
P1476
Potent immune responses and in ...... sed on rare human serotype 28.
@en
P2093
C Richter King
Cassandra Nyberg-Hoffman
Christoph A Kahl
Jason G D Gall
Jessica Bonnell
Megan Fultz
Suja Hiriyanna
P2860
P304
P356
10.1016/J.VACCINE.2010.06.050
P407
P577
2010-06-29T00:00:00Z